Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative

Authors:
  • RGR Gupta
    R Gupta
  • PHP Huamani
    P Huamani
  • VLV Leimane
    V Leimane
  • APAD Pasechnikov
    AD Pasechnikov
  • TTTE Tupasi
    TE Tupasi
  • KVK Vink
    K Vink
  • EJE Jaramillo
    E Jaramillo
  • MEMA Espinal
    MA Espinal

  • 1 November 2004
    • journal article
    • research article
    • Vol. 8  (11) , 1382-1384
    • PMID:15581210
Abstract
Adverse events associated with second-line drugs have been mentioned as obstacles in the management of multidrug-resistant tuberculosis (MDR-TB). Data on adverse events were collected from five DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and the Russian Federation (Tomsk Oblast). The results show that among 818 patients enrolled on MDR-TB treatment only 2% of patients stopped treatment, but 30% required removal of the suspected drug(s) from the regimen due to adverse events. The study shows that adverse events are manageable in the treatment of MDR-TB in resource-limited settings provided that standard management strategies are applied.